Phase 3 CANOPY-HCH-3 met primary endpoint: VOXZOGO +2.33 cm/yr in hypochondroplasia
BioMarin reported results from its Phase 3 study of VOXZOGO (vosoritide) for Hypochondroplasia on May 20, 2026. The study met its main goal.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary
- Company
- BioMarin Pharmaceutical Inc. BMRN
- Drug
- VOXZOGO (vosoritide)
- For
- Hypochondroplasia
- Stage
- Phase 3 · the last stage before a drug can be approved
- When
- May 20, 2026
- Source note
- The Phase 3 CANOPY-HCH-3 study of VOXZOGO in children with hypochondroplasia met its primary endpoint with a statistically significant increase in annualized growth velocity at Week 52 versus placebo (LS mean difference +2.33 cm/yr, p<0.0001), plus significant gains in standing height, height Z-score and arm span. BioMarin planned a US sNDA submission in Q3 2026.
- Checked
- Checked by a person when it was added
- Source: biomarin.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- BMRN headlines on this site
BMN 351 DMD program update by year-end 2026, expected in Q4 2026 (Oct–Dec) (no exact date yet). A company milestone for BioMarin (BMN 351 for Duchenne muscular dystrophy (exon 51 skipping)): a step in the program rather than a decision or a data readout.
More details
- Entry
- BMN 351 DMD program update by year-end 2026 · Company milestone
- Drug
- BMN 351
- For
- Duchenne muscular dystrophy (exon 51 skipping)
- Stage
- Early clinical
- When
- Q4 2026 · the company gave a window, not a day
- Source note
- Q2 2026 earnings PR (Aug 6, 2026) frames the known H2 2026 BMN 351 update as 'by year-end', i.e., Q4 2026 under the date-mapping rules.
- Checked
- Checked by a person when it was added
- Verify it
- Source: prnewswire.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- BMRN headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
The FDA is due to decide by Feb 28, 2027 whether to approve BioMarin’s VOXZOGO (vosoritide) for Achondroplasia in children (conversion of accelerated approval to full approval). Approval clears it for sale in the US; a rejection usually arrives as a letter listing what has to be fixed first.
More details
- Entry
- PDUFA date for VOXZOGO full-approval sNDA in achondroplasia · FDA decision due (PDUFA date)
- Drug
- VOXZOGO (vosoritide)
- For
- Achondroplasia in children (conversion of accelerated approval to full approval)
- Stage
- sNDA under FDA review
- When
- Feb 28, 2027
- Source note
- FDA accepted BioMarin's sNDA for full approval of VOXZOGO in children with achondroplasia with a PDUFA target action date of February 28, 2027, supported by long-term data including adult height, body proportionality, and arm span.
- Checked
- Checked by a person when it was added
- Verify it
- Source: investors.biomarin.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- Drugs@FDA ↗ — search the drug name for approval letters
- BMRN headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
BioMarin expects to report results from its Phase 2/3 study of BMN 333 for Achondroplasia during 2027 (no exact date yet). Phase 2/3 is a combined mid- to late-stage study.
More details
- Entry
- BMN 333 long-acting CNP Phase 2/3 achondroplasia data update · Clinical trial results (readout / topline data)
- Drug
- BMN 333
- For
- Achondroplasia
- Stage
- Phase 2/3 · a combined mid- to late-stage study
- When
- 2027 · the company gave a window, not a day
- Source note
- Q2 2026 earnings PR (Aug 6, 2026); no half/quarter given.
- Checked
- Checked by a person when it was added
- Verify it
- Source: prnewswire.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- BMRN headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
BioMarin expects the FDA to decide on VOXZOGO (vosoritide) for Hypochondroplasia during 2027 (no exact date yet). An approval lets the company start selling it in that market.
More details
- Entry
- Potential FDA approval/launch of VOXZOGO in hypochondroplasia · Regulatory approval
- Drug
- VOXZOGO (vosoritide)
- For
- Hypochondroplasia
- Stage
- sNDA under FDA review
- When
- 2027 · the company gave a window, not a day
- Source note
- Q2 2026 earnings PR (Aug 6, 2026); a PDUFA date should follow FDA acceptance of the recently submitted sNDA.
- Checked
- Checked by a person when it was added
- Verify it
- Source: prnewswire.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- Drugs@FDA ↗ — search the drug name for approval letters
- BMRN headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page